According to VCBeat, CytoNiche Biotechnology ("CytoNiche") recently announced the completion of a Series A financing of tens of millions, with participation from Beijing Shoufazhan Tianji Fund, Detong Capital and an international industrial group. Haoyue Capital acted as the sole financial advisor for the latest round.
CytoNiche focuses on the research and development of 3D micro-tissue engineering technology. The core technology comes from the project conducted by Tsinghua University. Based on its original research technology, CytoNiche has launched a series of products and services, including customized, large-scale, automatic and intelligent stem cell culture and amplification process, 3D stem cell microtissue regeneration therapies and 3D cell high-throughput drug screening products.
CytoNiche now has a 1000m2 R&D center and a 2000m2 GMP production base. The company has obtained over 30 patents and published more than 30 articles in well-known international journals such as Nature Materials, PNAS, Nature Communication, Biomaterials, and have been widely reported at home and abroad.
3D FloTrix® series products developed by CytoNiche are an original overall solution that can realize the large-scale culture and amplification of stem cells, as well as an innovation in pharmaceutical injection for stem cells.
The three-dimensional culture system of CytoNiche's stem cells can solve many problems such as low efficiency of traditional two-dimensional amplification culture of stem cells, difficulties in continuous cultivation, inability to efficiently expand, unstable quality of stem cell products and so on.
CytoNiche's products have achieved mass production in the GMP system and stable sales. Its core products are in the stage of clinical application. The company has signed strategic cooperation agreements with a number of firms of IND applications and new drug applications to jointly promote the development of new drugs in cellular therapy.
About Detong Capital
Detong Capital is a private equity investment firm that provides growth capital to early and expansion-stage companies. It invests in dynamic businesses that have high growth potential, strong management teams, and demonstrated revenue models in both technology-based and traditional industries.